Market Research Logo

Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2018

Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, “Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2018 provides an overview of Myelodysplastic Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Myelodysplastic Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Myelodysplastic Syndrome Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Myelodysplastic Syndrome
Feb 20, 2018: Actinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
Feb 20, 2018: Onconova Announces Presentation on Rigosertib Sodium at 2018 American Chemical Society National Meeting and Expo
Feb 20, 2018: H3 Biomedicine Preclinical Proof-of-Concept Data on First-in-Class Spliceosome-Modulator Therapy for Genomically Identified Patients with Hematological Cancers Published in Nature Medicine
Feb 08, 2018: GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Chemotherapy
Feb 05, 2018: Trethera Announces FDA Clearance of Investigational New Drug Application for TRE-515
Feb 02, 2018: Onconova Announces Presentation Of Mechanism Of Action Studies Of Rigosertib Combination With Azacitidine At American Association For Cancer Epigenetics Research Conference
Jan 29, 2018: BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentinib (BGB324) supports its potential as cornerstone of cancer therapy
Jan 17, 2018: Onconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim Analysis
Jan 02, 2018: Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARa Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients
Dec 14, 2017: Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300
Dec 11, 2017: Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers
Dec 11, 2017: New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML
Dec 11, 2017: OHSU and Aptose Present CG’806 Preclinical Data at ASH 59th Annual Meeting
Dec 11, 2017: Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART Molecule, Presented at 59th Annual ASH Meeting
Dec 10, 2017: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology
Dec 10, 2017: Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients
Dec 09, 2017: Amphivena Presents Preclinical Data at ASH That Points to a Potentially New Treatment for MDS Patients
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source
List of Tables
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Region, 2018*
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, G7 Countries (%), 2018*
Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, E7 Countries (%), 2018*
Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Phase, 2018*
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
Myelodysplastic Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
List of Figures
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2018*
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, G7 Countries (%), 2018*
Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, E7 Countries (%), 2018*
Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2018*
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
Myelodysplastic Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
GlobalData Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report